Efficacy and Tolerability of Intravenous Paricalcitol in Calcitriol-Resistant Hemodialysis Patients with Secondary Hyperparathyroidism: 12-Month Prospective Study

Basit Öğe Kaydı
dc.contributor.authorTonbul, Halil Zeki
dc.contributor.authorSolak, Yalçın
dc.contributor.authorAtalay, Hüseyin
dc.contributor.authorTürkmen, Kültigin
dc.contributor.authorAltıntepe, Lütfullah
dc.date.accessioned2020-03-26T18:25:25Z
dc.date.available2020-03-26T18:25:25Z
dc.date.issued2012
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractRationale/objectives: Data are limited regarding the use of paricalcitol in calcitriol-resistant patients with secondary hyperparathyroidism (SHPT). We aimed to evaluate the effects of paricalcitol in calcitriol-resistant hemodialysis patients with SHPT. Methods: This is a 12-month, open-label, prospective study. Forty patients with calcitriol-resistant and/or calcitriol-intolerant SHPT were included. After a washout period, all patients converted to paricalcitol with a 1: 3 conversion ratio. Serum calcium and phosphorus were monitored monthly, while serum intact parathyroid hormone (iPTH) once in every 3 months. Paricalcitol dose was reduced or discontinued in case of hypercalcemia and/or hyperphosphatemia. Pre- and posttreatment electrolyte and iPTH values were compared with Student's t-test and Wilcoxon signed-rank test, respectively. Main findings: Forty patients completed the study. Mean initiation dose of paricalcitol was 23 +/- 7 mu g/week. Mean serum calcium was 8.9 +/- 0.8 mg/dL at baseline and 9.4 +/- 0.7 mg/dL at study end (p = 0.07). Mean monthly serum phosphorus levels stayed stable. Paricalcitol was effective in reducing iPTH levels when compared with pretreatment values (747.9 +/- 497.2 pg/mL, 307.3 +/- 417.1 pg/mL, respectively; p < 0.001). Thirty-two patients had to discontinue intravenous (IV) paricalcitol at some time during their treatment. Main reasons for discontinuation were as follows: hyperphosphatemia (58%), hypercalcemia (25%), and iPTH < 150 pg/mL (17%). Principle conclusions: Paricalcitol was found to be effective in reducing iPTH levels in calcitriol-resistant patients with SHPT despite relatively frequent drug discontinuation rates.en_US
dc.identifier.doi10.3109/0886022X.2011.647298en_US
dc.identifier.endpage303en_US
dc.identifier.issn0886-022Xen_US
dc.identifier.issn1525-6049en_US
dc.identifier.issue3en_US
dc.identifier.pmid22251408en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage297en_US
dc.identifier.urihttps://dx.doi.org/10.3109/0886022X.2011.647298
dc.identifier.urihttps://hdl.handle.net/20.500.12395/28004
dc.identifier.volume34en_US
dc.identifier.wosWOS:000300558700007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.relation.ispartofRENAL FAILUREen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectcalcitriolen_US
dc.subjecthemodialysisen_US
dc.subjectparicalcitolen_US
dc.subjectresistanceen_US
dc.subjectsecondary hyperparathyroidismen_US
dc.titleEfficacy and Tolerability of Intravenous Paricalcitol in Calcitriol-Resistant Hemodialysis Patients with Secondary Hyperparathyroidism: 12-Month Prospective Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu